Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your doctor has decided to prescribe you a medication called guselkumab (a biologic treatment) for your condition, and you are about to start it or have just been enrolled before your first dose
- You have an official diagnosis of moderate-to-severe Crohn's Disease or Ulcerative Colitis documented in your medical records
- You are willing and able to sign a consent form allowing the trial team to check your medical records as required
Who may not be able to join:
- You have a medical reason why guselkumab is not safe for you to take (confirm with trial site)
- You are currently taking part in another clinical trial that involves a treatment or intervention
- You have previously been treated with certain medications that target a protein called IL-23, specifically guselkumab (Tremfya®), risankizumab (Skyrizi®), or mirikizumab (Omvoh®) — however, if you have previously taken a drug called ustekinumab, you may still be eligible
- You have already been treated with more than 4 different advanced therapies (such as biologics or certain tablets) for your bowel condition
- You are not able to give your own informed consent to take part in the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen-Cilag Limited Clinical Trial, Janssen-Cilag Limited
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants Achieving Clinical Remission for Crohn's Disease (CD) as Measured by Harvey-Bradshaw Index (HBI); Number of Participants Achieving Clinical Remission for Ulcerative Colitis (UC) as Measured by Partial Mayo Score (PMS); Number of Participants Achieving Clinical Response for CD as Measured by HBI; Number of Participants Achieving Clinical Response for UC as Measured by PMS; Number of Participants Achieving Corticosteroid-free Remission for CD as Measured by HBI; Number of Participants Achieving Corticosteroid-free Remission for UC as Measured by PMS; Number of Participants...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.